CELL INTELLIGENCE · 肿瘤细胞治疗研究

工程化改造 CAR-T 细胞分泌 VEGF 中和 scFv 增强对实体瘤的抗肿瘤活性

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.

CDK12 的泛癌多组学特征分析及越南天然产物新型抑制剂的虚拟筛选

Pan-cancer multi-omics characterization of CDK12 and virtual screening of Vietnamese natural products for novel inhibitors.

重组 AAV 基因转移：在免疫调节和癌症治疗中的新兴应用

Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy.

体外及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效的嵌合抗原受体 (CAR)-NK92 细胞

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of o

我们的结果表明，CD44v6-CAR-NK92 细胞可能是一种有吸引力的治疗实体瘤的治疗剂。

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

三级淋巴结构通过重塑冷肿瘤微环境实现从冷到热的转变

Tertiary lymphoid structures achieve 'cold' to 'hot' transition by remodeling the cold tumor microenvironment.

靶向 LLT1 作为多种实体瘤中对现有检查点疗法无应答的癌症患者的潜在免疫治疗选择

Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.

生物标志物分析显示，在来自 TCGA 和临床数据库的患者队列中，LLT1 表达升高与免疫抑制性 TME 存在明确关联。因此，本研究为将 LLT1 作为潜在靶点以改善 LLT1 上调的 ICI 无应答患者的临床反应提供了基础。

表达抗 CD47 抗体的溶瘤病毒联合替莫唑胺增强乳腺癌脑转移治疗

Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide.

决定肿瘤细胞命运的吞噬调节因子 CD47 的肿瘤研究进展（综述）

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).

实体瘤的 CAR-T 细胞治疗

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors.